Sinopsis
Michael Frazis and guests discuss their market views and latest investment ideas.
Episodios
-
Episode 31: Gaming, eSports and chipmakers - Ben Krochmal joins us for a deep dive
07/07/2020 Duración: 43minGaming is one of the more exciting industries in technology right now. We discuss the opportunities and precedents for Twitch and streaming phenomenon. Ben also takes us through leading chipmakers like NVDIA. 0:32 - Long term trends for Nvidia 2:16 - Demand for Nvidia GPU's in Data centres 3:03 - Use of Nvidia chips for Crypto mining 4:38 - Semiconductors are on the forefront for everything 5:46 - Nvidia compared to other chip makers, AMD and Intel 8:35 - Bitcoin mining economics 9:22 - Technology companies that 'miss the trend' 10:40 - Moore's Law and what it means for CPU's and GPU's 11:58 - What is the go-to for gamers now? 12:50 - Interesting stocks and opportunities for gaming - the shift to mobile gaming 15:35 - American vs Chinese Mobile games 16:10 - Sea's mobile game Freefire's recent success 18:40 - Ben's experience with mobile gaming 19:44 - Popularity of the MOBA category specifically League of Legends 21:05 - Online viewership of League of Legends worlds more than 44M concurre
-
Episode 30: Plug Power, Solaredge, and a market update
04/07/2020 Duración: 16minPeter Stevens rejoins us to discuss some of our environmentally friendly investments. 0:30 - The continued dispersion between technology and the rest of the market 0:50 - The successes of Pinduoduo, Carvana and Afterpay 1:28 - Frazis Capital's successful diversification away from a highly concentrated portfolio 2:33 - Comparing today's hot tech businesses with the hot auto businesses of the past 3:00 - Michael introduces Plug Power (NASDAQ:PLUG), a hydrogen fuel cell manufacturer and one of the fund's most exciting holdings 5:00 - Introducing the Frazis Capital Youtube channel 5:50 - Michael introduces Chinese software firm, Kingsoft Corporation (HKG:3888) 7:00 - Peter and Michael discuss the various factors influencing the systematic underpricing of IPOs 10:10 - Cochlear's (ASX:COH) lucrative discounted capital raising 11:35 - The value that Frazis Capital can add to your portfolio 12:40 - Solaredge (NASDAQ:SEDG), an innovative Israeli solar provider and portfolio position 14:40 - ESG investing
-
Episode 29: Alexander Portz joins us to talk growth investing in the UK and abroad
10/06/2020 Duración: 57minAlexander began his career investing in technology for UK funds management giant Neptune, before joining London-based VC fund Redline Capital. It's rare indeed to speak to someone with experience across the public and private side of tech investing. We had a fascinating chat covering robotic process automation, innovation investing, and life in venture capital vs public markets. https://www.linkedin.com/in/alexander-portz-3a265236/ https://www.redline-capital.com/ 0:50 - Alex talks about his start in public markets 2:30 - Tech investing at Neptune Capital 3:50 - Alex discusses a high-performing company during his time at Neptune 6:20 - Michael and Alex discuss a stand-out semiconductor manufacturer 8:05 - The importance of investing in high quality companies 9:25 - Investing using an EV/Sales ratio and sales growth (Shopify as an example) 9:50 - The opportunity presented by Blue Prism 10:00 - Alex and Michael extensively discuss Blue Prism 15:05 - Alex outlines his firm's investment in Catalytic,
-
Episode 28: Moving up against the market
16/05/2020 Duración: 55minEti Amegor of Axius Partners & www.suitsandkicks.com joins us to talk allocating and investing in the strange current environment. 0:52 - Opportunities during the coronavirus 1:55 - Current investor trends regarding liquidity 3:30 - The new private equity fund being launched by Eti's firm 6:30 - Why the coronavirus is the best environment for active investment managers 8:00 - Life Sciences stocks and the coronavirus 9:30 - Mike talks through Moderna, which focuses on drug discovery and development based on messenger RNA 10:50 - Eti and Mike talk Afterpay (again) 14:00 - The endgame... Afterpay vs Paypal 16:55 - Why Frazis Capital does not buy Big Tech 17:10 - Mike introduces MercadoLibre, a new portfolio holding 18:30 - Mike introduces Sea, another new portfolio holding 20:00 - Shopify has performed superbly... is it still worth the valuation? 23:55 - Investment thematics within Frazis Capital Partners 25:20 - Mike discusses three digital health investment opportunities 28:30 - Frazis Capital's rece
-
Episode 27: Coronacrisis Recovery?
17/04/2020 Duración: 42minPeter Stevens joins us once again - and will upload notes for this shortly.
-
Episode 26: Deeper into the coronacrisis
10/04/2020 Duración: 48minMichael Frazis and Peter Stevens discuss the latest developments.
-
Episode 25: Market sell-off and interesting times
09/03/2020 Duración: 25minPeter Stevens joins us to talk about the market sell-off, how we're positioned, and interesting opportunities that we've found. If you'd like to know more about us see: www.fraziscapitalpartners.com Peter writes his own market commentary here: https://insufficientcapital.com/ 0:24 – Peter wipes away his tears 0:50 – There’s growth and then there’s growth (e.g. Afterpay vs Zip) 1:30 – Why you should pay up for quality businesses 2:17 – Illiquidity during sell-offs 2:50 – Electro Optic Systems (ASX:EOS), a great business that does not fit ESG criteria 3:35 – Analysing quality within the WAAAX (the Australian equivalent of the FAANG) 4:54 – Frazis Capital’s avoidance of education and tourism stocks 5:50 – Peter and Michael look at Qantas (ASX:QAN), Australia’s major airline 7:40 – Theoretically maintaining a 20% cash position 8:00 – Michael discusses Ray Dalio’s “Principles” 9:25 – Carvana (NYSE:CVNA), Frazis Capital’s largest coronavirus casualty 10:22 – Afterpay’s (ASX:APT) accelerating growth and
-
Episode 24: Coronavirus - what's going on? Claude joins us to talk about the impact on specific stocks, and we also cover Afterpay's results
28/02/2020 Duración: 24minThree things you didn't know about the the virus, an Aussie company that stands to benefit, and two in the United States. Afterpay's results... this was a quick one, but a good one. If you'd like to know more about us see: www.fraziscapitalpartners.com You can find Claude at www.arichlife.com.au 0:50 – Michael gives an update on the underlying science of the latest coronavirus 1:44 – The importance of understanding the spike protein 2:05 – Why the coronavirus is so much more infectious than SARS 3:14 – Claude shares his thoughts on how the spread of the coronavirus may play out 3:30 – Michael discusses the recent coronavirus tests using SARS antibodies 5:02 – Claude reveals his plan of action if Australian coronavirus transmission increases 6:20 – Discussion of Swine Flu 7:30 – The issue with unpredictable virus mutation 9:30 – The effects of temperature on the coronavirus 11:00 – Discussion of Biotron (ASX:BIT), an Australian biotech which could combat coronavirus 11:23 – Claude discusses his position
-
Episode 23: Time to sell? Mike and Claude go through Shopify, EML and other cult stocks in the market right now
25/02/2020 Duración: 44minEpisode 23: Time to sell? Mike and Claude go through EML, Shopify, Wisetech and other cult stocks in the market right now. If you'd like to know more about us see: www.fraziscapitalpartners.com 1:08 - Michael and Claude discuss EML Payments (ASX:EML) 1:44 - The ethical dilemma of EML’s gambling exposure 2:40 - Problems relating to the sale high growth stocks 3:16 - EML’s acquisition of Prepaid Financial Services 3:44 - Accusations from Ownership Matters concerning EML 6:50 - The issue with ‘EBITDA’ as a financial metric 9:05 - Michael and Peter Stevens’ thoughts on EML 10:03 - The long-term threat for EML 10:50 - The macroeconomic impact of the coronavirus 12:10 - Does coronavirus’ growing risk as a pandemic change Frazis Capital’s view of market conditions? 13:45 - Chinese stimulus countering the impacts of the coronavirus 15:35 - Luxury brands negatively impacted by the coronavirus as shopping numbers fall 16:58 - Many Australian technology businesses are still trading at high multiples of sales
-
Episode 22: Aussie growth stocks for the next decade? Mike and Claude talk Polynovo, Avita, Audinate, Pro Medicus and Afterpay
16/02/2020 Duración: 49minMike and Claude from A Rich Life (https://arichlife.com.au/) talk Australian growth stocks for the next decade. If you'd like to know more about us see: www.fraziscapitalpartners.com 0:38 - Claude's background and time at Motley Fool 4:30 - Pro Medicus (PME:ASX) recommendation and discussion 6:38 - Claude touches on his investment style 8:08 - Pro Medicus as a platform business rather than just a software business 8:30 - Pro Medicus - the numbers 10:20 - Claude dives into Pro Medicus' two key revenue streams 11:50 - Michael introduces Alteryx (AYX:NYSE) and accounting standards 14:45 - Claude's worst mistake (Touchcorp) 17:30 - Claude touches on cognitive errors 18:10 - Michael discusses Afterpay (APT:ASX), comparing it to some US tech investments 19:25 - Afterpay, the YOLO stock? 21:55 - The network effects of Afterpay 22:30 - Consumer behaviour of Afterpay customers 24:38 - Claude introduces Avita Healthcare (AVH:ASX), discussed in Frazis Capital's previous podcast 26:58 - Avita's opportunity in vitil
-
Episode 21: A high-tech company with explosive growth...and various other science things you don't want to miss
12/02/2020 Duración: 45minMatthew Shribman has accumulated over 25 million views across platforms for his 'Science in the Bath' series, available here: https://www.youtube.com/channel/UCoSRNBi6F4jN0CYq-sRcOHQ We talk about how birds literally 'see' the Earth's magnetic field, and cover Twist Bioscience, a company that's revolutionizing gene synthesis. Twist is working on DNA as a viable storage medium for computers, drug discovery, genetic sequencing and synthetic biology. This is a little more sciencey than usual, but I think you will enjoy! If you'd like to know more about us see: www.fraziscapitalpartners.com Timestamps: 0:11 -- Introducing Matthew Shribman 3:00 -- Whale carbon sequestration 4:30 -- Matthew's bird migration project at Oxford 6:50 -- How bird compasses work 9:03 -- How to photograph molecules with lasers, prisms and mirrors 15:49 -- Our new investment in Twist - revolutionizing DNA synthesis 17:53 -- Twist's take on drug development 19:08 -- DNA as a storage medium for computers 24:33
-
Episode 20: Australian bushfires, and two Aussie companies revolutionising burns treatment
05/02/2020 Duración: 32minPeter Stevens joins us to discuss Coronavirus and two Aussie burns innovators: Avita and Polynovo. Find more information about us here: www.fraziscapitalpartners.com And please get in touch if you have questions you'd like us to answer on the podcast, suggestions or feedback. If you'd like to know more about us see: www.fraziscapitalpartners.com 00:28 – Coronavirus, and how to calculate the real mortality rate 02:20 – The common cold is a coronavirus 04:18 – Market performance during past pandemics 05:00 – Why you shouldn’t sell your stocks because of the coronavirus! 07:00 – Australian bushfiresand two Aussie burns innovators 07:50 – Introducing Polynovo (ASX:PNV) and how the firm’s improving the existing standard-of-care for serious burns over the incumbent, Integra 14:40 – Avita (ASX:AVH) 15:12 – Avita's RECELL system 16:16 – How ReCell improves recovery 17:10 – The opportunity in Vitiligo 19:12 – Skin grafts 19:47 – How Avita fi
-
Episode 19: How we’re different
14/01/2020 Duración: 28minPeter Stevens rejoins us to discuss investment strategy and our top new picks.
-
Episode 18: Portfolio updates and new ideas with Peter Stevens
20/12/2019 Duración: 42minPeter Stevens joins us to talk about some of our long held investments and latest new ideas. Peter Stevens has rejoined Frazis Capital Partners, and writes his own market blog here: https://insufficientcapital.com/
-
Episode 17: Strategy, biotech and growth investing with Eti Amegor
29/11/2019 Duración: 01h12minA wide-ranging conversation with Eti Amegor, of Axius Partners. We discuss growth investing, Carvana and our top biotech picks, including a drug to reduce stress. Eti runs a podcast himself and asked some tough questions! This one was a lot of fun. Eti's podcast 'Suits and Kicks' is available here: https://podcasts.apple.com/au/podcast/suits-and-kicks/id1454889632 And you can find more about us here: www.fraziscapitalpartners.com
-
Episode 16: Paul Brennan goes deep on the Australian economy
08/11/2019 Duración: 50minPaul Brennan is a markets veteran with over 20 years at Citigroup in Australia, most recently as Chief Economist. He now consults for a wide range of clients, and in his spare time, offers his expertise to university students. It's always great to have a chat with someone who measures their market experience in decades, so this was a real privilege. We go deep on economics, the Australian economy, what it was like in the 90s and where things might be going next. Paul Brennan can be found here: https://au.linkedin.com/in/paulbrennanassociates And you can find more information about us and subscribe to our newsletters here: www.fraziscapitalpartners.com
-
Episode 15: Growth opportunities and the software sell-off
29/10/2019 Duración: 43minPeter Stevens joins us to talk about the recent growth sell off and the new opportunities and investment ideas we're looking at.
-
Episode 14: Value is Dead, Long Live Value
11/10/2019 Duración: 42minThere are many ways to create value without showing after-tax profits. Michael Frazis and Mario Emmanuel discuss new approaches. https://www.fraziscapitalpartners.com/post/value-is-dead-long-live-value
-
Episode 13: A chat with Anna Satouris about energy, markets and prices
23/09/2019 Duración: 16minRecorded 16 September, 2019, this podcast features Anna Satouris and a discussion around energy, markets and prices.
-
Episode 12: We discuss a strong reporting season and our fee rebate to long term clients
30/08/2019 Duración: 24minMichael Frazis and Anna Satouris discuss Carvana, Afterpay, Pinduoduo and our recent fee rebate to long term clients.